Browsing by Subject "Benznidazole"

Now showing items 1-7 of 7

    • Acute chagas outbreaks: molecular and biological features of Trypanosoma cruzi isolates, and clinical aspects ... 
      Díaz, Martha Lucía; Leal, Sandra; Mantilla, Julio César; Molina Berríos, Alfredo Enrique; López Muñoz, Rodrigo; Solari Illescas, Aldo; Escobar, Patricia; González Rugeles, Clara Isabel (BioMed Central, 2015)
      Background: Outbreaks of acute Chagas disease associated with oral transmission are easily detected nowadays with trained health personnel in areas of low endemicity, or in which the vector transmission has been interrupted. ...
    • Aspirin-triggered resolvin D1 reduces parasitic cardiac load by decreasing inflammation in a murine model ... 
      Carrillo, Ileana; Nonato Rabelo, Rayane Aparecida; Barbosa, César; Rates, Mariana; Fuentes Retamal, Sebastián Andrés; González Herrera, Fabiola; Guzmán Rivera, Daniela Inés; Quintero, Helena; Kemmerling Weis, Ulrike; Castillo, Christian; Machado, Fabiana; Díaz Araya, Guillermo; Maya, Juan (Public Library Science, 2021)
      Chagas disease, caused by the protozoan Trypanosoma cruzi, is endemic in Latin America and is widely distributed worldwide because of migration. In 30% of cases, after years of infection and in the absence of treatment, ...
    • Current and developing therapeutic agents in the treatment of Chagas disease 
      Apt Baruch, Werner (2010)
      Chagas disease must be treated in all its stages: acute, indeterminate, chronic, and initial and middle determinant chronic, due to the fact that DNA of the parasite can be demonstrated by PCR in chronic cases, where optical ...
    • Effects of buthionine sulfoximine nifurtimox and benznidazole upon trypanothione and metallothionein proteins ... 
      Maya Arango, Juan; Rodríguez, Andrés; Pino, Laura; Pabón, Adriana; Ferreira, Jorge; Pavani, Mario; Repetto Scaramelli, Yolanda; Morello Casté, Antonio (Society of Biology of Chile, 2004)
      Proteins rich in sulfhydryl groups, such as metallothionein, are present in several strains of the parasite Trypanosoma cruzi, the etiological agent of Chagas' disease. Metallothionein-like protein concentrations ranged ...
    • Notch receptor expression in Trypanosoma cruzi‐infected human umbilical vein endothelial cells treated with ... 
      Campos Estrada, Carolina; González Herrera, Fabiola; Greif, Gonzalo; Carrillo Werner, Ileana; Guzmán Rivera, Daniela; Liempi Manquel, Ana; Robello, Carlos; Kemmerling Weis, Ulrike; Castillo Rivas, Christian; Maya Arango, Juan Diego (Wiley, 2020)
      Chagas disease is a vector-borne disease caused by the protozoan parasite Trypanosoma cruzi. Current therapy involves benznidazole. Benznidazole and other drugs can modify gene expression patterns, improving the response ...
    • Pentamidine antagonizes the benznidazole's effect in vitro, and lacks of synergy in vivo: Implications about ... 
      Seguel, Verónica; Castro, Lorena; Reigada, Chantal; Cortés, Leonel; Díaz, María V.; Miranda, Mariana R.; Pereira, Claudio A.; Lapier, Michel; Campos Estrada, Carolina; Morello Casté, Antonio; Kemmerling Weis, Ulrike; Maya, Juan D.; Lopez Muñoz, Rodrigo (Elsevier, 2016)
      Benznidazole is the first-line drug used in treating Chagas disease, which is caused by the parasite Trypanosoma cruzi (T. cruzi). However, benznidazole has limited efficacy and several adverse reactions. Pentamidine is ...
    • Treatment of Chagas disease 
      Apt Baruch, Werner (Elsevier, 2017)
      Although Chagas disease has existed for at least 9000 years, its treatment is recent: the internationally accepted drugs nifurtimox and benznidazole date from the 1970s. Both drugs are effective in acute cases, in congenital ...